Chinese pharma must use collaborative deals to leverage IP expertise
The recent spate of partnerships agreed between Western and Chinese pharmaceutical businesses underscores the continued need for collaboration to fully leverage the Chinese market. But while foreign life sciences companies pursue joint ventures with…
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.